Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 11, 2017. The document serves as a transaction notification reporting insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share acquisition transactions.
| Transaction Date | Instrument | Price per Share | Total Volume | Exchange |
|---|---|---|---|---|
| October 10, 2017 | Ordinary Shares (25p each) | £15.1765 | 128 Shares (Aggregated) | London Stock Exchange (XLON) |
Material Changes
The filing does not contain comparative financial data or material changes to the company's business operations versus prior periods. It reports routine acquisitions under the Company's Share Reward Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions reported are standard acquisitions of partnership and matching shares by senior executives.
Important Facts for Investors
- Insider Activity: Nine senior executives, including the CEO (Ms E Walmsley) and CFO (Mr S Dingemans), acquired shares on October 10, 2017.
- Transaction Type: All transactions were acquisitions under the Company's Share Reward Plan, consisting of partnership shares and matching shares.
- Volume: Individual transactions ranged from 16 to 18 shares per executive, totaling 128 shares across all reported individuals.
- Price: All shares were acquired at a uniform price of £15.1765.
- Scope: This filing is a regulatory disclosure of insider holdings and does not reflect the company's overall financial health or operational results.